Latest news with #CARBOGENAMCIS
Business Standard
2 days ago
- Business
- Business Standard
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: Aarau site: installation of 850-litre reactors and 0.4 m agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. Neuland site: installation of 850-litre reactors and 0.4 m agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.
Business Upturn
2 days ago
- Business
- Business Upturn
Dishman Carbogen shares in focus after Swiss subsidiary signs CHF 25 million co-investment agreement
Shares of Dishman Carbogen Amcis Ltd. could see increased investor interest after its Swiss subsidiary, CARBOGEN AMCIS AG, announced a strategic co-investment exceeding CHF 25 million with a key Japanese client. The deal is aimed at expanding antibody-drug conjugate (ADC) manufacturing capabilities at the company's Aarau and Neuland sites in Switzerland. The investment will specifically support the production of a drug linker used in commercial ADCs, an area witnessing rising global demand. Under the agreement, both sites will undergo significant upgrades: Aarau will see the installation of 850-litre reactors and agitated filter dryers by Q1 2027, while similar enhancements at Neuland are scheduled for completion by Q3 2027. This development marks the second major collaboration between CARBOGEN AMCIS and the same customer, building on a 2021 joint funding project for the Bubendorf site. The announcement reaffirms the company's growing importance in handling complex, high-potency APIs and delivering end-to-end CDMO (Contract Development and Manufacturing Organization) services across global markets. Given the scale and strategic nature of this co-investment, the move is expected to bolster Dishman Carbogen's long-term growth outlook and may reflect positively in its stock performance in the coming sessions. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Yahoo
22-04-2025
- Business
- Yahoo
CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License from Chinese NMPA
CARBOGEN AMCIS Shanghai BUBENDORF, Switzerland, April 22, 2025 (GLOBE NEWSWIRE) -- CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company is pleased to announce that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China's National Medical Products Administration (NMPA). The NMPA approval followed a rigorous review focused on GMP compliance and operational readiness. The Shanghai site successfully met all regulatory expectations, reflecting the maturing of its operations and the strength of its quality systems. This milestone marks a pivotal step in CARBOGEN AMCIS' expansion in China and reinforces its commitment to customers in the region. Located in the Shanghai Chemical Industry Park (SCIP), the 40,000m² site is a fully self-supporting facility equipped for early-phase research and development, pilot scale production and commercial GMP manufacture. Its services range from raw materials to APIs, including high potency material handling and micronization. With equipment in four segregated units and reactor capacities from 50 to 6,300 litres, the facility is built for flexibility, efficiency and scalability. The site employs over 140 people and brings together an international team of specialists whose expertise, combined with advanced infrastructure, enables the delivery of tailored, scalable solutions to customers worldwide. 'This achievement underscores our team's commitment, disciplined execution, and the robustness of our Quality Management System, which has been rigorously aligned with both corporate and Chinese regulatory requirements,' said Simone Maggi, Quality Head - CARBOGEN AMCIS Shanghai site. 'In addition to our core manufacturing capabilities, we're proud that the Shanghai site is equipped to handle highly potent compounds up to category 3 and provide full GMP product release and analytical support,' said Harry Wong, Country Manager, CARBOGEN AMCIS Shanghai. 'This license is a testament to the strength of our team and demonstrates our ability to execute seamless technology transfers and align with the highest quality standards across CARBOGEN AMCIS' global network.' Stephan Fritschi, CEO at CARBOGEN AMCIS, stated: 'Securing the Drug Manufacturing License not only demonstrates the operational readiness of our Shanghai site but also reflects the strength of our global quality culture. This achievement strengthens our long-term goal of becoming a trusted partner in the Chinese pharmaceutical market.' He added, 'I would like to take this opportunity to express my gratitude to every member of our site team for their dedication and to the Executive Team for their continuous support and trust throughout this journey.' For further information contact: Denise Neufeld +41 79 213 06 60 CARBOGEN AMCIS ( is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India. A photo accompanying this announcement is available at
